Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of Mineralocorticoid Receptors in Vascular Function
NCT00759525Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2002
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glycyrrhetinic acid in apparent mineralocorticoid excess (AME), sponsored by Brigham and Women's Hospital. Started Feb 2002; status: completed.
02
Drugs
glycyrrhetinic acid
03
Conditions
apparent mineralocorticoid excess (AME)
Beyond the preview
Go deeper on NCT00759525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759525.